BPC-157 vs Semax
Side-by-Side Comparison
| Attribute | Bpc 157 | Semax |
|---|---|---|
| Category | Healing & Recovery | Nootropic / Neuroprotective |
| Mechanism | BPC-157 acts through multiple overlapping pathways. It promotes angiogenesis by upregulating VEGFR2 and VEGF expression, and activates nitric oxide synthesis via the Src kinase-caveolin-1 pathway and... | Semax is a brain-selective heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro, MW ~813.88 g/mol) that crosses the blood-brain barrier via intranasal absorption. |
| Evidence Rating | C — Phase I–II Clinical Trials | D — Preclinical |
| Clinical Status | Research-only / No approved human indication. Phase I oral safety trial completed; Phase II UC trial underway. | Approved in Russia and Ukraine for stroke and cognitive disorders; not approved elsewhere |
| Safety Profile | No completed randomized controlled human clinical trials for safety assessment; Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology | Generally favorable safety profile with uncommon mild side effects and no dependence potential; No significant hormonal effects despite ACTH-fragment origin — brain-selective mechanism reduces systemic side effects |
| Route | Subcutaneous (preferred), Intramuscular, or Oral | Intranasal (preferred) or Subcutaneous |
| Dose Range | 200–600 mcg/day SC; oral doses studied at 1–6 mg in clinical trials | Intranasal: 200–600 mcg per nostril, 2–3x daily; SC: 200–600 mcg daily |
| Frequency | Once daily | 2–3 times daily (intranasal); once daily (SC) |
| Molecular Weight | ~1419.5 g/mol | ~813.9 g/mol |
| Half-Life | ~15 min IV (animal data); oral activity persists 24+ hours | ~3–5 minutes; intranasal extends effective duration |
Overview
BPC-157 and Semax are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
BPC-157 — Mechanism & Evidence
BPC-157 is a synthetic 15-amino-acid peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419.5 g/mol) derived from a protein found in human gastric juice. It has demonstrated robust regenerative and cytoprotective effects across hundreds of animal studies spanning tendon, ligament, muscle, bone, nerve, GI tract, and blood vessel healing. However, human clinical data is extremely limited — only three pilot studies have examined BPC-157 in humans as of 2025 (knee pain n=16, interstitial cystitis n=12, IV safety n=2). The FDA classifies it as Category 2, prohibiting compounding, and WADA bans its use in sports.
Key claims: Accelerates tendon and ligament healing; Heals gut lining and treats leaky gut; Reverses NSAID-induced GI damage.
Semax — Mechanism & Evidence
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from adrenocorticotropic hormone (ACTH) fragment 4-10, with an added Pro-Gly-Pro sequence for metabolic stability. Molecular weight is approximately 813.88 g/mol (formula C37H51N9O10S). Discovered in Russia during the 1980s as part of government-funded neuropeptide research, it is approved in Russia and Ukraine for the treatment of ischemic stroke, cognitive disorders, encephalopathy, and optic nerve atrophy. Despite its ACTH origin, Semax does not activate adrenal corticosteroid production, acting selectively on brain-specific pathways.
Key claims: Neuroprotective in stroke; Enhances memory and cognitive function; Increases BDNF levels.
Shared Research Applications
These peptides target different research areas. BPC-157 focuses on Injury Recovery, Gut Health, while Semax targets Cognitive Enhancement.
Safety Considerations
BPC-157: No completed randomized controlled human clinical trials for safety assessment Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology FDA previously classified BPC-157 as Category 2 (significant safety concerns); removed from Category 2 on April 15, 2026. PCAC review pending July 2026 to determine compounding eligibility. FDA noted insufficient human safety data and potential immunogenicity risks.
Semax: Generally favorable safety profile with uncommon mild side effects and no dependence potential No significant hormonal effects despite ACTH-fragment origin — brain-selective mechanism reduces systemic side effects Administered intranasally — mild nasal irritation possible; proper spray technique recommended
Related Products
Related Research News
Boost Focus and Clarity with Selank and Semax Duo
Selank and Semax, synthetic peptides from Russian research labs, offer complementary cognitive benefits. Selank reduces anxiety and sharpens attention by balancing neurotransmitters and upregulating BDNF. Semax sustains focus through neuroprotection and neurotrophin enhancement, with studies showing improved memory under stress when used together.
BPC-157 Gut Health: Gastric Cytoprotection Studies
Research on BPC-157 began with gastric cytoprotection in the early 1990s, led by Sikiric and colleagues at the University of Zagreb. Studies show it protects against ethanol-induced lesions and NSAID damage in rat models, with effects linked to angiogenesis, prostaglandins, nitric oxide, and gut-brain signaling. This body of work highlights its stability for oral use and broad preclinical applications in GI models.
BPC-157 Shelf Life: Lyophilized vs Reconstituted Stability Guide
BPC-157 has a finite shelf life that varies by form and storage. Lyophilized powder lasts 12-18 months refrigerated or 24+ months frozen, while reconstituted solution holds for about 28 days under refrigeration. Factors like temperature, light, and handling influence stability, and researchers should watch for signs of degradation to ensure reliable results.